Literature DB >> 7538534

Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha.

P Szabolcs1, M A Moore, J W Young.   

Abstract

Human CD34+ bone marrow progenitors cultured in the presence of granulocyte-macrophage CSF (GM-CSF) develop along a myeloid pathway, and the addition of exogenous TNF-alpha leads to the differentiation of dendritic cells among the myeloid progeny. These bone marrow CD34+ -derived dendritic cell that develop during 2-wk culture have the same morphologic, phenotypic, and functional properties that distinguish mature dendritic cells in blood. c-kit ligand does not directly influence dendritic cell differentiation per se, but rather increases the total cell number in synergistic combination with GM-CSF and TNF-alpha. This degree of expansion translates into an effective yield of approximately 1.7 x 10(6) mature dendritic cells per single ml of normal adult human bone marrow, compared with approximately 10(6) dendritic cells usually obtained from 450 to 500 ml of peripheral blood. In addition to dendritic cells that constitute approximately 10 to 15% of the total myeloid progeny, the cultures contain monocytes/macrophages and intermediate granulocytic precursors. Monocytes/macrophages and dendritic cells together comprise all of the class II MHC-positive progeny. Sorted cells bearing the CD14+ HLA-DR+ phenotype of mature monocytes are at least 1.5 to 2 logs less active than CD14- HLA-DR+ dendritic cells as stimulators in the allogeneic MLR, even though both CD14+ and CD14- subpopulations share expression of several costimulatory ligands. The synergistic combination of c-kit ligand, GM-CSF, and TNF-alpha therefore expands substantial numbers of immunostimulatory CD14- HLA-DR+ dendritic cells from defined CD34+ progenitors in human bone marrow. This should facilitate the use of dendritic cells in the manipulation of T cell-mediated immune responses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7538534

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  Expression of the RelB transcription factor correlates with the activation of human dendritic cells.

Authors:  G J Clark; S Gunningham; A Troy; S Vuckovic; D N Hart
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

Review 2.  Prospects for immune reconstitution in HIV-1 infection.

Authors:  N Imami; F Gotch
Journal:  Clin Exp Immunol       Date:  2002-03       Impact factor: 4.330

3.  Humoral and cell-mediated adaptive immune responses are required for protection against Burkholderia pseudomallei challenge and bacterial clearance postinfection.

Authors:  Gareth D Healey; Stephen J Elvin; Margaret Morton; E Diane Williamson
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.

Authors:  Jacalyn Rosenblatt; Baldev Vasir; Lynne Uhl; Simona Blotta; Claire Macnamara; Poorvi Somaiya; Zekui Wu; Robin Joyce; James D Levine; Dilani Dombagoda; Yan Emily Yuan; Karen Francoeur; Donna Fitzgerald; Paul Richardson; Edie Weller; Kenneth Anderson; Donald Kufe; Nikhil Munshi; David Avigan
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

5.  Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.

Authors:  X Cao; W Zhang; J Wang; M Zhang; X Huang; H Hamada; W Chen
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

6.  CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells.

Authors:  L J Zhou; T F Tedder
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

7.  Human dendritic cells handling of binding, uptake and degradation of free and IgG-immune complexed dinitrophenylated human serum albumin in vitro.

Authors:  M Larsson; J Berge; A G Johansson; U Forsum
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

8.  Dendritic cell maturation and antigen presentation in the absence of invariant chain.

Authors:  P Rovere; V S Zimmermann; F Forquet; D Demandolx; J Trucy; P Ricciardi-Castagnoli; J Davoust
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

9.  The generation of immunocompetent dendritic cells from CD34+ acute myeloid or lymphoid leukemia cells.

Authors:  Takahide Tsuchiya; Masao Hagihara; Yasuhito Shimakura; Yoko Ueda; Balgansuren Gansuvd; Batmunkh Munkhbat; Hiroyasu Inoue; Kei Tazume; Shunichi Kato; Tomomitsu Hotta
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

10.  Adjuvant GM-CSF improves survival in high-risk stage iiic melanoma: a single-center Study.

Authors:  Travis E Grotz; Lisa Kottschade; Emily S Pavey; Svetomir N Markovic; James W Jakub
Journal:  Am J Clin Oncol       Date:  2014-10       Impact factor: 2.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.